Dianthus director granted 6,090 stock options
Dianthus Therapeutics director Steven J. Romano received a grant of stock options covering 6,090 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Dianthus Therapeutics director Steven J. Romano received a grant of stock options covering 6,090 shares of common stock. The options have an exercise price of $89.63 per share and expire on May 21, 2036. According to the terms, all 6,090 underlying shares will vest in full on the earlier of the first anniversary of the May 21, 2026 grant date or the company’s 2027 annual meeting of stockholders, provided he continues serving the company through that vesting date.
Insider Trade Summary
Grant/Award: 6,090 shares
Grant/Award
1 txn
Insider
Romano Steven J.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 6,090 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 6,090 contracts (Direct)
Footnotes (1)
- F1. The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Key Figures
Option grant size: 6,090 options
Exercise price: $89.63 per share
Expiration date: May 21, 2036
+2 more
5 metrics
Option grant size
6,090 options
Stock Option (Right to Buy) granted May 21, 2026
Exercise price
$89.63 per share
Exercise price of stock option grant
Expiration date
May 21, 2036
Option expiration for 6,090-share grant
Underlying shares
6,090 shares
Common stock underlying granted options
Post-transaction derivative holdings
6,090 options
Total derivative securities held after grant
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, grant, award, or other acquisition, +2 more
6 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 89.6300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-05-21T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
vest in full financial
"will vest in full on the date that is the earlier"
Annual Meeting of Stockholders financial
"the Issuer's 2027 Annual Meeting of Stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Dianthus Therapeutics (DNTH) director Steven J. Romano report on this Form 4?
Steven J. Romano reported receiving a grant of stock options for 6,090 shares of Dianthus Therapeutics common stock. These options were awarded at an exercise price of $89.63 per share and represent compensation rather than an open-market stock purchase or sale.
How many Dianthus Therapeutics (DNTH) options were granted to Steven J. Romano?
He was granted stock options covering 6,090 shares of Dianthus Therapeutics common stock. This full amount is reported as held following the transaction, indicating the award created a new option position rather than modifying an existing derivative holding.
What is the exercise price and expiration date of Steven J. Romano’s DNTH options?
The stock options have an exercise price of $89.63 per share and expire on May 21, 2036. This sets the fixed price Romano would pay per share if he chooses to exercise the options before expiration, subject to vesting conditions.
When do Steven J. Romano’s Dianthus Therapeutics (DNTH) options vest?
All 6,090 underlying shares vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual meeting of stockholders. Vesting is contingent on Romano’s continued service with Dianthus Therapeutics through that vesting date.
Does this Form 4 show Steven J. Romano buying or selling DNTH stock on the market?
No, the Form 4 shows a grant of stock options as compensation, coded as a grant or award acquisition. It does not report an open-market purchase or sale of Dianthus Therapeutics common stock by Romano on the transaction date.
How many DNTH derivative securities does Steven J. Romano hold after this transaction?
Following the reported grant, Romano holds 6,090 derivative securities in the form of stock options. These options each relate to one share of Dianthus Therapeutics common stock and are held directly, as indicated in the ownership coding.
AI-generated analysis. How Rhea-AI works. Not financial advice.
